Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced Curtis Rambaran, MD, previously Silence’s Vice President, Head of Clinical Science, has been promoted to Chief Medical Officer, and Marie […]

Johnson & Johnson MedTech Acquires Laminar, Inc.

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to […]

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

– Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders – Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence […]

RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company’s Business Advisory Board

PETALUMA, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Stephen Tannenbaum to the Business Advisory Board of RetinalGeniX. Mr. Tannenbaum will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire […]

Nanox Announces Third Quarter of 2023 Financial Results and Provides Business Update

Reports progress towards global supply chain development and commercial deployment Ended the third quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $95.6 million Management to host conference call and webcast Tuesday, November 28, 2023 at 8:30 AM ET Management to host investor day on December […]

Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities

The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. BRAINTREE, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced […]

HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

Southlake, TX, Nov. 20, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the closing of its license agreements with […]

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board

CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company’s PH-HFpEF […]

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of […]